In hypoxia-induced PAH models, targeting the glycolytic bypass enzyme G6PD pharmacologically decreases M2a macrophage markers, TNFα+ platelets, and pro-inflammatory factor accumulation in the lungs, suggesting its potential as a therapeutic target (146). Here, TNF is linked to pulmonary arterial hypertension.